AstraZeneca PLC · LSE:AZN
AstraZeneca — Shareholder Meeting (2006)
5 slides from AstraZeneca's shareholder meeting presentation, Oct 17, 2006
Slide 1: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking Statements In order to utilise the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995, AstraZeneca is providing the following cautionary statement. This presentation contains forward-looking statements with re
Slide 2: Headline results FY 05
Headline results FY 05 2005 2004 Actual CER $m $m growth growth Sales 23,950 21,426 +12% +10% Operating profit 6,502 4,547 +43% +39% EPS Before exceptionals $2.91 $2.01 +44% +41% Statutory $2.91 $2.18 +33% +30% Dividends $1.30 $0.94 Share repurchase $3,001m $2,212m 3 Headline results FY 05 2005 2004
Slide 3: Strong momentum of growth portfolio; Headline results Q1 06
Strong momentum of growth portfolio 12,000 10,000 8,000 $m 6,000 4,000 2,000 0 Q1 00 Q1 01 Q1 02 Q1 03 Q1 04 Q1 05 Q1 06 Seroquel Arimidex Nexium Symbicort Crestor MAT 5 Headline results Q1 06 2006 2005 Actual CER $m $m growth growth Sales 6,180 5,743 +8% +12% Operating profit 1,976 1,453 +36% +33%
Slide 4: Headline results FY 05; Relative share price performance
Headline results FY 05 2005 2004 Actual CER $m $m growth growth Sales 23,950 21,426 +12% +10% North America 11,747 10,507 +12% +11% Europe 8,463 7,649 +11% +8% Japan 1,527 1,430 +7% +8% Rest of World 2,213 1,840 +20% +15% 7 Relative share price performance 170 160 150 140 130 120 110 100 90 80 03-Ja
Slide 5: AstraZeneca priorities
AstraZeneca priorities Optimising top-line growth Expanding and delivering our pipeline utilising internal and external sources of products and technologies Improving productivity Enhancing our reputation with our stakeholders by: Understanding their needs Living up to our core values an